Genome-wide detection of LOH in prostate cancer using human SNP microarray technology
- PMID: 12659810
- DOI: 10.1016/s0888-7543(03)00020-x
Genome-wide detection of LOH in prostate cancer using human SNP microarray technology
Abstract
Loss of heterozygosity (LOH) of chromosomal regions is crucial in tumor progression. In this study we assessed the potential of the Affymetrix GeneChip HuSNP mapping assay for detecting genome-wide LOH in prostate tumors. We analyzed two human prostate cell lines, P69SV40Tag (P69) and its tumorigenic subline, M12, and 11 prostate cancer cases. The M12 cells showed LOH in chromosomes 3p12.1-p22.1, 11q22.1-q24.2, 19p13.12, and 19q13.42. All of the prostate cases with informative single-nucleotide polymorphism (SNP) markers showed LOH in 1p31.2, 10q11.21, 12p13.1, 16q23.1-q23.2, 17p13.3, 17q21.31, and 21q21.2. Additionally, a high percentage of cases showed LOH at 6p25.1-p25.3 (75%), 8p22-p23.2, and 10q22.1 (70%). Several tumor suppressor genes (TSGs) have been mapped in these loci. These results demonstrate that the HuSNP mapping assay can serve as an alternative to comparative genomic hybridization for assessing genome-wide LOH and can identify chromosomal regions harboring candidate TSGs implicated in prostate cancer.
Similar articles
-
High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines.Oncogene. 2004 Apr 8;23(15):2716-26. doi: 10.1038/sj.onc.1207329. Oncogene. 2004. PMID: 15048096
-
A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.BMC Cancer. 2010 May 12;10:195. doi: 10.1186/1471-2407-10-195. BMC Cancer. 2010. PMID: 20462409 Free PMC article.
-
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis.Cancer Res. 2003 May 1;63(9):2216-22. Cancer Res. 2003. PMID: 12727842
-
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7. Adv Exp Med Biol. 1997. PMID: 9321930 Review.
-
Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays.Cancer Genet Cytogenet. 2005 May;159(1):53-7. doi: 10.1016/j.cancergencyto.2004.09.014. Cancer Genet Cytogenet. 2005. PMID: 15860358 Review.
Cited by
-
DNA microarrays: a powerful genomic tool for biomedical and clinical research.Mol Med. 2007 Sep-Oct;13(9-10):527-41. doi: 10.2119/2006-00107.Trevino. Mol Med. 2007. PMID: 17660860 Free PMC article. Review.
-
Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA.Nucleic Acids Res. 2004 May 17;32(9):e69. doi: 10.1093/nar/gnh072. Nucleic Acids Res. 2004. PMID: 15148342 Free PMC article.
-
Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.Br J Cancer. 2008 Jul 8;99(1):78-82. doi: 10.1038/sj.bjc.6604441. Epub 2008 Jun 24. Br J Cancer. 2008. PMID: 18577987 Free PMC article.
-
Genomic profiling of prostate cancers from African American men.Neoplasia. 2009 Mar;11(3):305-12. doi: 10.1593/neo.81530. Neoplasia. 2009. PMID: 19242612 Free PMC article.
-
Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.PLoS One. 2014 Jan 28;9(1):e84745. doi: 10.1371/journal.pone.0084745. eCollection 2014. PLoS One. 2014. PMID: 24489653 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
